©2024 Stanford Medicine
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Not Recruiting
Trial ID: NCT01677390
Purpose
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of
SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell
carcinoma.
Official Title
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression
- Previously treated with at least 1 tyrosine kinase inhibitor (TKI)
- Measurable disease
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate lung and renal function
Exclusion Criteria:
- Prior treatment with anti-CD70-directed therapy
- Received more than one prior treatment with an mTOR inhibitor
Intervention(s):
drug: SGN-75
drug: everolimus
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061